Related Experiment Video
Updated: Mar 21, 2026

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
Published on: May 30, 2025
Natural Products and lncRNAs in Renal Cell Carcinoma: Emerging Therapeutic Approaches
Ahmed S Doghish1,2, Mai A Abd-Elmawla3, Nora M Aborehab4
1Department of Biochemistry, Faculty of Pharmacy, Badr University in Cairo (BUC), Cairo, Egypt.
Abstract:
Renal cell carcinoma (RCC) is a malignant neoplasm arising from the renal epithelium and constitutes approximately 2% of global cancer diagnoses and mortalities. With increasing prevalence, RCC remains a pressing clinical challenge, particularly because of its resistance to conventional therapies and poor outcomes in advanced stages. Long noncoding RNAs (lncRNAs) have been proposed as key molecular mediators in RCC, orchestrating critical pathways such as epithelial-to-mesenchymal transition (EMT), cellular proliferation, apoptosis, angiogenesis, and metastasis. Their roles in therapeutic resistance, including chemoresistance and radioresistance, further highlight their impact on treatment outcomes. Additionally, the potential of natural compounds such as curcumin, quercetin, and resveratrol to target lncRNA-mediated pathways has garnered attention, offering insights into novel therapeutic strategies. This review examines the biogenic pathways and multifaceted functions of lncRNAs, shedding light on their influence on RCC pathophysiology and posttranscriptional regulation. In addition, this review emphasizes the repercussions of natural compounds as lncRNA-targeted therapies, thus offering a comprehensive perspective on emerging strategies that may lead to more effective and personalized treatments.
Insights
Long noncoding RNAs (lncRNAs) are key in renal cell carcinoma (RCC) progression and treatment resistance. Natural compounds show promise for targeting lncRNAs in novel RCC therapies.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Renal cell carcinoma (RCC) is a prevalent cancer with poor outcomes, often resistant to conventional treatments.
- Long noncoding RNAs (lncRNAs) are implicated in RCC pathogenesis, influencing key processes like proliferation, metastasis, and therapeutic resistance.
- Existing therapies for advanced RCC are limited, necessitating exploration of novel therapeutic targets and strategies.
Purpose of the Study:
- To review the biogenic pathways and functions of lncRNAs in renal cell carcinoma (RCC).
- To elucidate the role of lncRNAs in RCC pathophysiology, posttranscriptional regulation, and therapeutic resistance.
- To explore the potential of natural compounds in targeting lncRNA-mediated pathways for novel RCC treatment strategies.
Main Methods:
- Literature review of studies on lncRNAs in renal cell carcinoma (RCC).
- Analysis of lncRNA involvement in critical cellular pathways (EMT, proliferation, apoptosis, angiogenesis, metastasis).
- Examination of lncRNA roles in chemoresistance and radioresistance in RCC.
- Investigation into natural compounds (curcumin, quercetin, resveratrol) targeting lncRNA pathways.
Main Results:
- lncRNAs are crucial molecular mediators in RCC, regulating key oncogenic pathways.
- lncRNAs significantly contribute to chemoresistance and radioresistance in renal cell carcinoma (RCC).
- Natural compounds demonstrate potential for targeting lncRNA-mediated pathways in RCC.
Conclusions:
- lncRNAs represent significant molecular players in renal cell carcinoma (RCC) development and progression.
- Targeting lncRNAs with natural compounds offers a promising avenue for developing novel and personalized RCC therapies.
- Further research into lncRNA-targeted therapies could improve treatment outcomes for renal cell carcinoma (RCC) patients.
Related Concept Videos
lncRNA - Long Non-coding RNAs
lncRNA - Long Non-coding RNAs
Non-LTR Retrotransposons
MicroRNAs
MicroRNAs
Types of RNA
RNA Performs Diverse...

